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Delphi survey
Lukas M Wildi1*, Anita Hensel2, Maria Wertli2, Beat A Michel1 and Johann Steurer2Abstract
Background: Inclusion/exclusion criteria and baseline characteristics are essential for assessing the applicability of
trial results to a given patient and the comparability of study populations for meta-analyses. This Delphi survey
aimed to generate a set of baseline characteristics for describing patients with knee osteoarthritis enrolled in clinical
studies.
Methods: Survey participants comprised clinical experts (n = 23; mean age 54 y; from 4 continents) that had
authored at least two randomized trials on knee osteoarthritis. First, given a prepared list of baseline patient
characteristics, the experts were asked to add characteristics they considered important for assessing comparability
of patient populations in different trials that evaluated the efficacy of non-surgical interventions for treating knee
osteoarthritis. Next, they were asked to rate the importance of each characteristic, on a scale of 0 (not important) to
10 (highly important), according to three outcome categories: pain, function, and structure.
Results: Participants identified 121 baseline characteristics. A rating ≥7 points was assigned to 39 characteristics
(e.g., age, depression, global knee pain, daily dose of pain killers, Kellgren-Lawrence grading); of these, 20 were
related to pain, 15 to function, and 23 to structural outcomes. Global knee pain was the only baseline characteristic
that fulfilled among experts the predefined consensus criteria.
Conclusions: Experts identified a large number of characteristics for describing patients with knee osteoarthritis.
Disagreement and uncertainty prevailed over the relevance of these characteristics. Our findings justified further
efforts to define appropriate, broadly acceptable sets of baseline characteristics for describing patients with knee
osteoarthritis.
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After reading and critically appraising a publication on
the effects of a particular treatment, clinicians must con-
sider the patients to which the reported results might
apply. The study authors typically present inclusion/ex-
clusion criteria in the Methods section and the baseline
characteristics of the included patients in the Results
section (typically in Table 1). Inclusion/exclusion criteria
inform readers how eligible patients were selected (e.g.,
age, illness, duration of complaints, severity of illness, and* Correspondence: lukas.wildi@usz.ch
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reproduction in any medium, provided the orco-morbidities) for participating in the trial. Baseline char-
acteristics describe the participants within a given bound-
ary of inclusion/exclusion criteria. The reported baseline
characteristics represent, in general, prognostic factors
that can impact the future course of the illness. For ex-
ample, among patients with knee osteoarthritis, those with
knee malalignments have a less favorable future course
than patients without malalignments [1].
Detailed baseline characteristics of trial participants
are also important for researchers in conducting system-
atic reviews and meta-analyses. Guidelines for preparing
meta-analyses and systematic reviews recommend asses-
sing the comparability of patient populations in different
primary studies and determining whether it is reasonabled. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 List of relevant baseline characteristics
Outcome
Pain Function Structure
General information
Age Age Age
Gender Gender Gender
Activity level in daily life Activity level in daily life
Psychosocial factors
Pain catastrophizing
Anxiety and Fear
Depression Depression
Quality of life* Quality of life*
Information from history
Primary or secondary osteoarthritis
Duration since onset of symptoms
indicating knee osteoarthritis
Duration since onset of symptoms
indicating knee osteoarthritis
Duration since onset of symptoms indicating
knee osteoarthritis
Intermittent or constant pain Intermittent or constant pain
Pain remained constant or varied
in the last week
Average daily pain during the
last week
Average daily pain during the last week
Walking aid needed (e.g., cane/walker)
Global knee pain** Global knee pain** Global knee pain**
Waking up with pain
Weight bearing pain Weight bearing pain
Pain at rest
Pain when going down stairs
Function of knee*** Function of knee*** Function of knee***
Pain or reduced function in other
joints (hip/spine)
Pain or reduced function in other joints
(hip/spine)
Previous history of knee trauma
Previous history of meniscal tear or meniscectomy
Previous history of ACL§ rupture
Previous surgical intervention
Daily dose of pain killers (NSAIDs)
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Table 1 List of relevant baseline characteristics (Continued)
Information from physical examination
BMI BMI BMI
Physical functional ability; e.g.,
performance tests of baseline
physical ability (e.g., the Timed Up and
Go test or a 6-min walking test)
Lab results
Imaging results
Kellgren-Lawrence grading (weight bearing)
Bone marrow lesions
Joint space width
Synovitis (US§§, MRI§§§)
Effusion (US, MRI)
Involved joint compartment (i.e., patellofemoral
vs. tibiofemoral vs. combined etc.)
Meniscus tear
Meniscus extrusion
ACL tear
Cartilage abnormalities (MRI)
Malalignment (hip-knee-ankle mechanical axis)
Cartilage volume/thickness in the compartment
of interest (MRI)
Legend: List of baseline characteristics with a median rating of importance ≥7 according to three different outcome categories, based on the opinions of an expert panel.
Abbreviations: *e.g., SF-36; **e.g., VAS, WOMAC; ***e.g., WOMAC, Lequesne; § Anterior crucial ligament; §§ Ultrasound; §§§ Magnetic Resonance Imaging.
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priate comparison is possible only when the required
data are reported in primary studies. Reported baseline
characteristics may be incomplete. Improper attention
to the comparability between patients of different trials
may raise criticism of results. For example, a systematic
review that compared the effects of chondroitin or glu-
cosamine in patients with knee osteoarthritis should en-
sure the patient populations were comparable [5]. To
our knowledge, recommendations from experts are lack-
ing on selecting the most relevant baseline characteris-
tics for patients with osteoarthritis of the knee.
The aim of this survey was to generate a set of base-
line characteristics that could, based on expert opinions,
appropriately describe patients with knee osteoarthritis
enrolled in clinical studies.
Methods
We assembled an international panel of clinical experts
on osteoarthritis to generate a list of baseline character-
istics for describing patients included in clinical trials
with knee osteoarthritis. A preliminary list was prepared
and sent to these experts with the request that they add
patient characteristics that they considered relevant. In a
second round, the experts were asked to rate the rele-
vance of each patient characteristic.
Selection and recruitment of experts
We searched Medline and EMBASE to identify clinical
experts on osteoarthritis of the knee. The following
MESH terms were used: Osteoarthritis, Knee, Physical
Therapy Modalities, Steroids, Viscosupplementation,
Anti-Inflammatory Agents, Non-Steroidal, Randomized
controlled trial (a detailed list of the search strategy is
available upon request from the corresponding author).
The search was restricted to articles published between
the years 2007 and 2012. We included only studies that
evaluated the treatment effect of steroid injections, vis-
cosupplementation, non-steroidal analgesics, or physical
therapy. The aim, set arbitrarily, was to identify 20 experts
that would participate in our survey. From the list of all
authors, we selected those that co-authored three or more
trials plus a random sample of authors that were listed on
two publications. Based on the medical specialty and/or
affiliation mentioned in the publication, we categorized
authors into groups of clinically-oriented (e.g., rheumatol-
ogists, physiotherapists) or methodology-oriented (e.g.,
clinical epidemiologists, biostatisticians) researchers. Only
authors categorized as clinically-oriented researchers were
contacted for participation in the survey.
First round
The selected experts were contacted by E-mail and in-
formed about the aim of the study. Those that agreed toparticipate received a prepared form and a request to add
characteristics to complete a preliminary list of baseline
characteristics (indicated by § in Additional file 1).
The experts received the following information: Patients
with knee osteoarthritis have been included in four ran-
domized trials (A/B/C/D, Additional file 2). In each of the
four trials, one group of patients received an active treat-
ment X (non-surgical) and the other group a placebo. In
trials A and B, the outcome of interest was pain; in trials
C and D, the outcome was a functional parameter. The re-
sults between trials differed significantly. In trials A and C,
treatment X showed a significant benefit, and in trials B
and D, the identical treatment X showed no benefit. The
execution of the trials (intervention, treatment, meas-
urement of outcomes, randomization etc.) was identical;
however, one reason for the contradictory results may
have been the inclusion of different patient populations in
all four trials. Then, the experts were asked “From your
experience as a clinical expert, what baseline patient char-
acteristics would be necessary to identify patients to
whom the trial results might be applicable, and further-
more, to evaluate the comparability of the two populations
in trials A/B and C/D? The participants were asked to add
characteristics that they thought should be included in
an attached list of baseline characteristics. Participants
returned the completed lists by mail or fax.
Second round
Based on the answers from the first round of inquiries,
we updated the list of patient characteristics. To avoid
redundancy, nearly identical characteristics were merged
into one parameter. The final list included 121 items
that were assigned to one of six categories, including
general information about the patient (e.g., age, gender),
psychosocial factors (e.g., depression, anxiety), history (e.
g., duration of pain, pain provoking maneuvers), physical
examination results (e.g., periarticular tenderness, in-
stability), laboratory tests (e.g., C-reactive protein, serum
hyaluronic acid concentration), and imaging results (e.g.,
Kellgren-Lawrence grading, bone marrow lesion).
This updated list was sent to the experts that had returned
the questionnaire from the first round. The participants
were asked to rate the ‘importance’ of each baseline char-
acteristic on a scale of 0 to 10, where 0 indicated no im-
portance, and 10 indicated the utmost importance. We
informed participants that the ‘degree of importance’ was
related to two issues; first, the relevance of the characteris-
tic in identifying patients in daily practice to whom the re-
sults of a study were applicable; and, second, its usefulness
in meta-analyses for assessing the comparability of patient
populations from different primary trials for a potential
pooling of results.
We reasoned that the experts would probably estimate
the importance of baseline characteristics differently,
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asked the participants to rate each baseline characteristic
according to three different outcome categories; pain (e.g.,
VAS), function (e.g., WOMAC-function sub-score), and
structure (e.g., change of the joint space width over time).
Participants that completed both questionnaires were
asked to provide information about their age, gender,
and primary medical specialty. Completed question-
naires were returned by E-mail or fax. All experts that
responded in the first round were informed that they
would receive a voucher for $100 after returning the
completed questionnaire for round 2.
Statistical analysis
For this study, the medians and interquartile ranges for
each parameter were calculated to quantify the importance
assigned to single items. The median is a measure for the
average and the 25-75% interquartile range (IQR) and the
range are measures of dispersion of values. The median
value means that half of the values are below and half the
values above the median value. The 25-75% IQR is the dif-
ference between the values of the 25th and 75th percen-
tiles. The 0th and 100th percentiles (minimal and maximal
values) define the range. The final list only included base-
line characteristics with a median rating ≥7 (on a 0 to 10
point scale). We arbitrarily defined a consensus among ex-
perts as a rating with an interquartile range ≤4 (±2) points.
Ethical approval
This work did not involve human subjects or animals.
Thus, according to national laws and institutional regu-
lations, review board (IRB) approval was not necessary.
All experts acknowledged in the manuscript gave their
permission to list their names.
Results
Recruitment and selection of experts
Between 2007 and 2012, we identified 364 randomized
trials involving patients with osteoarthritis of the knee.
From 1149 authors, 76 were invited to participate in the
survey. Of those, 32 agreed to participate, and 23 finally
took part in both rounds. The mean age of the panel
members was 54 years (range 39 to 75 years); 7 of the
participants were female. Medical specialties of the panel
members included rheumatologists (n = 13), physiother-
apy (n = 6), rehabilitation medicine (n = 1), occupational
therapy (n = 1), orthopedic biomechanics (n = 1), and
musculoskeletal medicine (n = 1). Nine panel members
were from North America (USA/Canada), eleven from
Europe, two from Australia, and one from Asia.
Results of first round
Twenty-three of 32 experts returned the list with additional
baseline characteristics. The additions comprised a total of267 baseline characteristics in addition to the 30 char-
acteristics nominated in the first list sent out. After
deleting repeated characteristics and merging highly
similar characteristics, 121 remained in the final list
(Additional file 1).
Results of second round
All 23 participants from the first round completed the
questionnaire in round 2. The medians of the expert rat-
ings varied between 1 (e.g., click on knee motion) and
10 (e.g., global knee pain, WOMAC score).
To ensure the list of baseline characteristics remained
within reasonable limits, we only included characteristics
that had been rated a median of seven or above by the ex-
pert panel. A total of 39 characteristics fulfilled this criter-
ion; 20 were related to a pain-reduction outcome, 15 were
related to a functional improvement outcome, and 23 to
a structural improvement outcome. The list of baseline
characteristics with a median rating ≥7 is displayed in
Table 1. Details of the median, 25-75% interquartile range,
and the range of estimates are shown in Additional file 1.
Six baseline characteristics were rated ≥7 in all three out-
come categories (age, gender, BMI, global knee pain, func-
tion of knee, duration since onset of symptoms indicating
knee osteoarthritis).
A consensus on the relevance of a baseline characteris-
tic was arbitrarily defined as a calculated range of four
(± 2) points or less around the median. Only one param-
eter, the global knee pain (e.g., VAS, WOMAC), fulfilled
this criterion; all other characteristics listed in Table 1
displayed ranges greater than four points but are still
rated as relevant baseline characteristics.
Discussion
There were three main results of this study. First, experts
listed a large number of baseline characteristics that de-
scribed patients with osteoarthritis of the knee included in
trials that evaluated treatment effects. Second, experts
agreed on the relevance of only one baseline characteristic.
All other baseline characteristics received ratings scattered
over a broad range, which indicated disagreement among
experts. Third, the relevance of baseline characteristics
varied according to the outcome measure in a trial.
Researchers have published a number of relevant articles
that emphasized the definitions and measurements of out-
comes in clinical trials that evaluated treatment effects in
patients with knee osteoarthritis [6-9]. Despite a thorough
search in various databases, we could not find any publi-
cations that focused on how to select baseline characteris-
tics of patients that participated in trials on osteoarthritis
of the knee. However, we identified a few publications that
summarized the evidence for prognostic factors that cha-
racterized patients with knee osteoarthritis. Cheung et al.
[1] stated that strong or moderate evidence indicated that
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ritis, knee malalignment, and serum hyaluronic acid con-
centration; limited evidence indicated associations with
knee pain, synovitis, the adduction moment of the knee,
vitamin D and C concentrations, and MRI bone marrow le-
sions in the knee; and conflicting evidence indicated associ-
ations with body mass index, initial severity of x-ray
changes, cartilage oligomeric protein (Comp), and urinary
CTX-II. In a recent systematic review, Chapple et al. [10]
reported some of the same results. They found that age,
generalized osteoarthritis, varus knee alignment, and radio-
graphic features, particularly joint space narrowing were
strongly associated with prognosis. The latter review [10]
provided no specific statements about the prognostic rele-
vance of serum hyaluronic acid concentration.
In part, our results were in agreement with the previous
studies [1,10]; but in part, our findings disagreed with
those studies. For example, the panel members of our sur-
vey considered psychosocial factors important, e.g., anx-
iety and fear; however, the supporting evidence for these
factors appeared to be scarce. The most striking discrep-
ancy was the difference between the number of prognostic
factors gathered from the synthesis of original studies and
the number collected from the clinical experts of the
present study. The clinical experts listed a much higher
number of relevant factors than the numbers listed in the
current literature.
The results of our survey might be helpful for clini-
cians and researchers. This study aimed to provide guid-
ance to clinicians for assessing the applicability of trial
results to a different clinical application. After reading
the results of a clinical trial, the main task of the clin-
ician is to assess which patients might benefit from the
treatment. Apart from the inclusion/exclusion criteria,
the most significant information for this assessment are
the baseline characteristics of study participants. The
present study provides a list of relevant factors based on
clinical expert opinions. Clinicians can consult this list
to evaluate the comprehensiveness of the baseline char-
acteristics in the reports they are considering.
Researchers may also find this list of baseline charac-
teristics important for two reasons. First, our results
may inform the design of future trials in patients with
knee osteoarthritis. Researchers can consult the present
list of baseline characteristics for each outcome of inter-
est to decide which patient characteristics should be re-
ported. The careful selection and reporting of baseline
characteristics can facilitate the translation of research
results into patient care, and this increases the useful-
ness of trial results. Second, researchers may find the list
relevant when synthesizing the results of original studies.
Guidelines for preparing systematic reviews by meta-
analyses recommend checking the comparability of pa-
tient populations between original studies before poolingthe results to derive a single value [2,4,11]. A prerequis-
ite for this type of assessment is the availability of de-
tailed information about the distribution of baseline
characteristics among the patients included in the ori-
ginal studies.
Our study had both strengths and limitations. The
primary limitation, inherent in most surveys, was that a
different panel of experts may provide different results.
A strength was that the members of the panel were ex-
perts in the field and had authored two or more clinical
trials that evaluated the effects of treatments for patients
with osteoarthritis of the knee. Furthermore, we in-
cluded a large number of panel members, and they were
from different countries. A panel with about 15 mem-
bers is recommended for surveys to reach a consensus
or to assess the degree of disconsensus [12]. With 23
panelists, we exceeded that recommended number. The
panel member internationality assured a broad spectrum
of opinions and eliminated the domination of an opinion
based on a single clinic or region-specific beliefs. A
further limitation of our study was that, in the first ques-
tionnaire, we only included pain-related and functional
outcomes, but no structural outcomes. In the second
questionnaire, we included the structural outcomes. We
assume that the addition of an outcome parameter did
not impact the results different results.
Conclusions
In conclusion, it remains uncertain which baseline char-
acteristics are most important to collect and report in
knee osteoarthritis trials. We cannot claim that our re-
sults provided a standard for reporting baseline charac-
teristics. However, the results of this survey may serve to
guide clinicians and meta-analysts in assessing whether
the baseline characteristics of a given clinical trial are
comprehensively reported. In addition, we provided a list
of characteristics considered important for the respective
study outcomes, based on the opinions of an expert
panel. Finally, the extent of disagreement among experts
on the relevance of baseline characteristics should mo-
tivate further research.
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